Advances in Pharmacological Treatment of Recurrent or Metastatic Cervical Cancer postprint

Abstract: Cervical cancer has the highest incidence among the three major gynecological malignancies and ranks fourth in both incidence and mortality among female malignancies，with its incidence continuing to rise. Early-stage cervical cancer is primarily treated with surgery，while concurrent chemoradiotherapy is the main treatment for advanced stages. For recurrent or metastatic cervical cancer，systemic treatment is the primary approach. The survival rate of patients with recurrent or metastatic cervical cancer is low，prognosis is poor，and treatment options are limited. The pharmacological treatment of recurrent or metastatic cervical cancer has evolved through several stages，including cisplatin monotherapy，platinum-based doublet chemotherapy，targeted therapy represented by bevacizumab，immunotherapy，and antibody-drug conjugates. While a relatively systematic treatment guideline has been established，recent advancements in drug development，the continuous updating of clinical trial results，and the exploration of combination therapies with different mechanisms of action underscore the need for an updated summary of the progress in pharmacological treatments for recurrent or metastatic cervical cancer to help clinicians expand therapeutic options for patients.